Clinical Trial Information

Objective

Test whether amyloid PET imaging will lead to a ≥ 30% change between intended and actual patient management within 90 days in a composite measure consisting of the following: a) AD drug therapy; b) Other drug therapy; or c) Counseling about safety and future planning.

Key Eligibility

Medicare beneficiary 65 years of age or older with diagnosis of MCI or dementia, according to DSM-IV and/or National Institutes 4.1.3of Aging-Alzheimer’s Association criteria, verified by a dementia specialist within 24 months